Ionis Pharmaceuticals Inc (IONS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Ionis Pharmaceuticals Inc stock (IONS) is currently trading at $72.70. Ionis Pharmaceuticals Inc PS ratio (Price-to-Sales) is 12.20. Analyst consensus price target for IONS is $93.90. WallStSmart rates IONS as Sell.
- IONS PE ratio analysis and historical PE chart
- IONS PS ratio (Price-to-Sales) history and trend
- IONS intrinsic value — DCF, Graham Number, EPV models
- IONS stock price prediction 2025 2026 2027 2028 2029 2030
- IONS fair value vs current price
- IONS insider transactions and insider buying
- Is IONS undervalued or overvalued?
- Ionis Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- IONS Piotroski F-Score and Altman Z-Score
- IONS analyst price target and Smart Rating
Ionis Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Ionis Pharmaceuticals Inc (IONS) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Ionis Pharmaceuticals Inc (IONS) Key Strengths (2)
105.66% of shares held by major funds and institutions
Large-cap company with substantial market presence
Supporting Valuation Data
Ionis Pharmaceuticals Inc (IONS) Areas to Watch (8)
Company is destroying shareholder value
Losing money on operations
Revenue declining -10.30%, a shrinking business
Earnings declining -43.70%, profits shrinking
Company is losing money with a negative profit margin
Very expensive relative to growth, significant premium
Very expensive at 12.2x annual revenue
Very expensive at 23.5x book value
Supporting Valuation Data
Ionis Pharmaceuticals Inc (IONS) Detailed Analysis Report
Overall Assessment
This company scores 21/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 2 register as strengths (avg 9.5/10) while 8 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including PEG Ratio (25.70), Price/Sales (12.20), Price/Book (23.53) suggest expensive pricing. Growth concerns include Revenue Growth at -10.30%, EPS Growth at -43.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -70.80%, Operating Margin at -105.50%, Profit Margin at -40.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -70.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -10.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IONS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IONS's Price-to-Sales ratio of 12.20x trades at a deep discount to its historical average of 34.45x (5th percentile). The current valuation is 94% below its historical high of 192.83x set in Nov 2007, and 26% above its historical low of 9.66x in Nov 2011. Over the past 12 months, the PS ratio has compressed from ~13.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Ionis Pharmaceuticals Inc (IONS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Ionis Pharmaceuticals Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 944M with 10% decline year-over-year. The company is currently unprofitable, posting a -40.4% profit margin.
Key Findings
Spending 30% of revenue (280M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 10% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -40.4% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Ionis Pharmaceuticals Inc.
Bottom Line
Ionis Pharmaceuticals Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Ionis Pharmaceuticals Inc(IONS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.